Clinical Trial Update: A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma [Phase 1]

View source ↗

Summary

Phase Ib LXH254-centric combination study in non-small cell lung cancer and melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• LXH254

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer, Melanoma | Phase 1 | Status: TERMINATED